Theralase Technologies (TSE:TLT) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Theralase Technologies, a company focusing on innovative cancer treatments, reported a decrease in revenues and a net loss for the nine-month period ending September 30, 2024. Despite a significant international sales increase, overall revenue dropped by 12%, while operating expenses were reduced by 7%.
For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.
